TORONTO, Oct. 8 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that David Young, MD, President and Chief Executive Officer of ARIUS, has been invited to speak at the 15th annual BioPartnering Europe conference.
Dr. Young will present on Tuesday, October 9th at 11:45 am British Summer Time (BST) and will be available following his presentation. The conference is being held at the QEII Conference Centre in London, United Kingdom. Dr. Young will provide an overview of the Company's business and unique technology and will update the audience on milestones for the Company's lead programs in cancer. ARIUS has three lead programs focused on treatments for breast, prostate, colon and pancreatic cancers and is actively pursuing partnering opportunities to move the pipeline forward.
The BioPartnering Europe conference offers attendees an opportunity to meet face-to-face with key players in the pharmaceutical and biotechnology industry. Dr. Young will also be available for informal discussions during the Open House Presentations on Monday, October 8th from 10:30 am-12:30 pm BST at Booth No. 20. Additional information about the 15th annual BioPartnering Europe conference can be found at: http://www.techvision.com/bpe/
About ARIUS
ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 400 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit www.ariusresearch.com
Forward-Looking Statements
Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
%SEDAR: 00013708E